AUROPHARMA · Healthcare
Aurobindo Pharma Ltd. reported revenue of ₹8,853 cr for January to March 2026, +5.6% on the year and +2.4% on the quarter. It is the highest quarterly revenue in the last 12 quarters on record. Over the last four quarters revenue comes to ₹33,653 cr, +6.1% on the four before.
Operating profit (EBITDA) was ₹1,750 cr, a margin of 19.8%, −123 bps on the year and −74 bps on the quarter. It is the narrowest margin of the last 8 quarters (range 19.8% to 21.4%). Operating costs grew +7.3%, faster than revenue at +5.6%, so operating profit grew less than sales.
Net profit was ₹921 cr, +2.0% on the year and +1.2% on the quarter, with earnings per share of ₹15.86. Profit before other income, one-offs and tax fell 2.2%, so 4 points of the headline growth came from outside the core business. The tax rate of 29% is in line with its recent average. Profit over the last four quarters totals ₹3,503 cr, +0.5% on the four before.
Pharma quarters swing with US generic launches and price erosion, while India formulations grow more steadily. Currency gains and other income can be material, so headline profit needs a check against operating profit. The quarterly statements do not carry the US and India split, R&D spend and any FDA observations; those come with the filing read.
On earnings per share of ₹60.34 over the last four quarters, the stock at ₹1,660.50 trades at 27.5 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow filed with this quarter, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
This quarter's filing carries a balance sheet and a cash flow statement. The cash, receivables and borrowing checks run once the filing read is in.
| Metric | Q2 FY26 |
|---|---|
| US revenue ($ m) | 3,638 |
| Gross margin | 59.7% |
Read using the Pharmaceuticals framework (named in the filing read). Primary valuation lens: P/E excluding one-time exclusivity gains.
Read more closely in this sector: Status of each US-filed plant · Price erosion stated · One-product dependence.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7,352 cr | ₹7,580 cr | ₹7,567 cr | ₹7,796 cr | ₹7,979 cr | ₹8,382 cr | ₹7,868 cr | ₹8,286 cr | ₹8,646 cr | ₹8,853 cr | ₹9,150 cr | ₹10,263 cr |
| YoY | — | — | +10% | +8% | +9% | +11% | +4% | +6% | +8% | +6% | +16% | +24% |
| EBITDA margin | 21.7% | 21.9% | 21.4% | 20.1% | 19.8% | 21.0% | 20.4% | 20.3% | 20.5% | 19.8% | 20.6% | 21.0% |
| Other income, % of PBT | 13% | 1% | 17% | 11% | 13% | 10% | 9% | 9% | 9% | 9% | 17% | 10% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | −₹40.2 cr | — |
| Tax rate | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% | 33% |
| Net profit | ₹940 cr | ₹907 cr | ₹918 cr | ₹817 cr | ₹846 cr | ₹903 cr | ₹824 cr | ₹848 cr | ₹910 cr | ₹921 cr | ₹1,032 cr | ₹1,124 cr |
| YoY | — | — | +61% | +9% | −10% | −0% | −10% | +4% | +8% | +2% | +25% | +33% |
| Core profit YoY | — | — | +44% | +21% | −5% | −1% | −0% | +8% | +17% | −2% | +17% | +32% |
| EPS | ₹15.98 | ₹15.51 | ₹15.69 | ₹14.07 | ₹14.56 | ₹15.56 | ₹14.20 | ₹14.61 | ₹15.67 | ₹15.86 | ₹17.86 | ₹19.57 |
| Flags | · | · | 1 | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Aurobindo Pharma Ltd. reported revenue of ₹8,853 cr (+5.6% on the year) and net profit of ₹921 cr (+2.0% on the year) for January to March 2026.
Profit before other income, exceptional items and tax moved −2.2% on the year, against +2.0% for reported profit.
None of the 7 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.